In patients and animals with hypertension, sympathetic nervous system (SNS) activation is present. We have demonstrated that angiotensin II type 1 receptor (AT 1 R)-induced oxidative stress in the rostral ventrolateral medulla (RVLM), a vasomotor center in the brainstem, causes SNS activation in hypertensive rats. The aim of the present study was to determine whether orally administered AT 1 R blockers (ARBs) inhibit SNS activation through an anti-oxidant effect via inhibition of AT 1 R in the RVLM of hypertensive rats and, if so, whether the benefits are class effects of ARBs. Stroke-prone spontaneously hypertensive rats (SHRSPs), a hypertensive model with sympathoexcitation, were divided into four groups: SHRSPs treated with telmisartan (TLM), candesartan (CAN), or hydralazine (HYD) and a vehicle group (VEH). Although systolic blood pressure was reduced in the TLM, CAN and HYD groups to the same level, heart rate, SNS activation and oxidative stress in the RVLM were significantly lower in the TLM group only. The pressor effect caused by the microinjection of angiotensin II into the RVLM and the depressor effect caused by the microinjection of tempol, a superoxide dismutase mimetic, into the RVLM were both significantly smaller in TLM, but not in CAN or HYD. These results suggest that orally administered TLM inhibits SNS activation through an anti-oxidant effect via inhibition of AT 1 R in the RVLM of SHRSPs; these results are also independent of depressor effects and are not class effects of ARBs. Keywords: angiotensin II; brain; oxidative stress; sympathetic nervous system INTRODUCTION Sympathetic nervous system (SNS) activation is a main cause of the development and progression of hypertension. 1-4 SNS activation is mainly regulated by the brain, 5-7 and we have demonstrated in rat models with hypertension or heart failure that direct interventions to the brain have beneficial effects because of sympathoinhibition. [8] [9] [10] [11] [12] [13] [14] Particularly in the brain, SNS activation is mainly regulated by the rostral ventrolateral medulla (RVLM) in the brainstem, and the functional integrity of the RVLM is essential for the maintenance of basal vasomotor tone. 5, 6 We have demonstrated that oxidative stress in the RVLM produced by the angiotensin II type 1 receptor (AT 1 R) causes SNS activation. 11,14-17 Upregulation of the central AT 1 R is important in the pathophysiology of hypertension. 6,7 Microinjection of AT 1 R blockers (ARBs) into the RVLM or intracerebroventricular infusion of ARBs inhibits SNS activation in hypertensive rats. 15, [18] [19] [20] However, AT 1 R or oxidative stress in the RVLM have not been targets for the treatment of hypertensive patients because we do not have suitable oral agents to inhibit AT 1 R or oxidative stress in the RVLM of hypertensive patients.
INTRODUCTION
Sympathetic nervous system (SNS) activation is a main cause of the development and progression of hypertension. [1] [2] [3] [4] SNS activation is mainly regulated by the brain, [5] [6] [7] and we have demonstrated in rat models with hypertension or heart failure that direct interventions to the brain have beneficial effects because of sympathoinhibition. [8] [9] [10] [11] [12] [13] [14] Particularly in the brain, SNS activation is mainly regulated by the rostral ventrolateral medulla (RVLM) in the brainstem, and the functional integrity of the RVLM is essential for the maintenance of basal vasomotor tone. 5, 6 We have demonstrated that oxidative stress in the RVLM produced by the angiotensin II type 1 receptor (AT 1 R) causes SNS activation. 11, [14] [15] [16] [17] Upregulation of the central AT 1 R is important in the pathophysiology of hypertension. 6, 7 Microinjection of AT 1 R blockers (ARBs) into the RVLM or intracerebroventricular infusion of ARBs inhibits SNS activation in hypertensive rats. 15, [18] [19] [20] However, AT 1 R or oxidative stress in the RVLM have not been targets for the treatment of hypertensive patients because we do not have suitable oral agents to inhibit AT 1 R or oxidative stress in the RVLM of hypertensive patients.
Interestingly, previous animal studies have suggested that peripherally administered ARBs inhibit the central actions of angiotensin II in the brain. 16, [21] [22] [23] [24] [25] [26] [27] [28] We demonstrated that orally administered ARBs reduced oxidative stress in the brains of hypertensive rats 16, 27 and that orally administered telmisartan (TLM) inhibits SNS activation in hypertensive rats. 16 These results suggest that orally administered ARBs have the potential to inhibit SNS activation through reduction of oxidative stress via inhibition of AT 1 R in the RVLM. In a previous clinical study, TLM, an ARB, is effective in reducing short-term ambulatory blood pressure variability and SNS activation in hypertensive patients with diabetic nephropathy. 29 However, in other clinical studies, ARBs do not have the same beneficial effects on the autonomic nervous system. 30, 31 Moreover, it has not been determined whether the sympathoinhibition caused by orally administered ARBs is a class effect of ARBs. 32 Gohlke et al. 26 demonstrated that, following peripheral administration, TLM is able to penetrate the blood-brain barrier in a dose-and time-dependent manner to inhibit centrally mediated effects of angiotensin II and that the effects of ARBs might differ depending on the pharmacokinetics and properties of each drug. We hypothesized that orally administered TLM penetrates the blood-brain barrier to a greater extent than any other ARB.
In hypertensive patients, ARBs are preferable for hypertensive patients. 33 New mechanistic insight into antihypertensive treatment could be provided if systemic treatment with ARBs was shown to inhibit SNS activation through inhibition of AT 1 R in the brain of hypertensive patients. The aim of the present study is to investigate whether orally administered TLM inhibits SNS activation through the reduction of oxidative stress via inhibition of AT 1 R in the RVLM of hypertensive rats. If so, we also aim to determine whether the results are independent of its depressor effects and if these effects are class effects of ARBs. To this end, we divided stroke-prone spontaneously hypertensive rats (SHRSPs) with severe sympathetic hyperactivity, used as the hypertensive model into TLM-, CAN-, hydralazine (HYD)-or vehicle (VEH)-treatment groups. TLM and CAN are widely used ARBs, and both ARBs have powerful blood pressurelowering effects. 32 We determined SNS activation by 24-h urinary norepinephrine excretion and determined the oxidative stress in the RVLM using the thiobarbituric acid-reactive substance (TBARS) method. We also determined the activity of nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase, which is a key AT 1 Ractivated component in the creation of oxidative stress moieties in the RVLM. Furthermore, we also performed microinjections of angiotensin II, superoxide dismutase mimetic (tempol) or NAD(P)H oxidase inhibitor (apocynin) into the RVLM of each group.
METHODS Animals
This study was reviewed and approved by the committee on ethics for Animal Experiments, Kyushu University Graduate School of Medical Sciences, and conducted according to the Guidelines for Animal Experiments by the Kyushu University. Male SHRSPs and age-matched Wistar-Kyoto (WKY) rats (12 to 14 weeks old) weighing 350 to 425 g were fed standard feed during this protocol (SLC Japan, Hamamatsu, Japan). They were housed individually in a temperature-controlled room (22 to 23 1C) with a 12-h/12-h light-dark cycle (lights on at 0700 hours). We divided SHRSPs and the WKY rats into four groups: a TLM-treatment group (TLM rats), a CAN-treatment group (CAN rats), a HYD-treatment group (HYD rats) and a VEH-treatment group (VEH rats).
Oral administration of TLM, CAN or HYD
SHRSPs and WKY rats were treated for 4 weeks. TLM rats received TLM (2 mg kg À1 per day, dissolved in 0.5% methylcellulose) and were given this oral gavage once daily (Sigma-Aldrich, St Louis, MO, USA). CAN rats received CAN (2 mg kg À1 per day, dissolved in 0.5% methylcellulose) and were given this oral gavage once daily (Sigma-Aldrich). HYD rats received HYD and were given this oral gavage once daily (5 mg kg À1 per day, dissolved in drinking water) (Sigma-Aldrich). VEH rats received 0.5% methylcellulose by oral gavage once daily.
Measurement of blood pressure, heart rate and SNS activation Systolic blood pressure and heart rate were measured once weekly using the tail-cuff method (BP-98 A; Softron, Tokyo, Japan). At 4 weeks, we calculated urinary norepinephrine excretion for 24 h as an indicator of SNS activation as previously described. [9] [10] [11] Microinjection of angiotensin II, tempol or apocynin into the RVLM At the end of the study, we microinjected angiotensin II bilaterally into the RVLM of all rats (n ¼ 5 per group). To inhibit the local oxidative stress in the RVLM, we microinjected tempol (100 pmol) bilaterally into the RVLM of all rats (n ¼ 5 rats per group). To inhibit the NAD(P)H oxidase locally in the RVLM, we microinjected apocynin (1 nmol) bilaterally into the RVLM of all groups (n ¼ 5 per group). The doses of tempol or apocynin and the procedures of the microinjection are reported in our previous studies. 11, 15 
Measurement of TBARS in the RVLM
To obtain RVLM tissue, the rats were deeply anesthetized with sodium pentobarbital (100 mg kg À1 IP) and transcardially perfused with PBS (150 mol l À1 NaCl, 3 mmol l À1 KCl and 5 nmol l À1 phosphate; pH 7.4, 4 1C). The brains were quickly removed, and 1-mm thick sections were obtained with a cryostat at À7 ± 1 1C. The RVLM was defined according to a rat brain atlas as described previously 9, 11 and obtained using a punch-out technique. The RVLM tissues were homogenized in 1.15% KCl (pH 7.4), 0.4% sodium dodecyl sulfate and 7.5% acetic acid adjusted; the pH was adjusted to 3.5 with NaOH. Thiobarbituric acid (0.3%) was added to the homogenate. The mixture was maintained at 5 1C for 60 min followed by heating to 100 1C for 60 min. After cooling, the mixture was extracted with distilled water and n-butanolpyridine (15:1) and centrifuged at 1600 g for 10 min. The absorbance of the organic phase was measured at 532 nm. The amount of TBARS was determined by absorbance, as described previously. 11,15
Measurement of NAD(P)H oxidase activity
At the end of the study, NAD(P)H-dependent superoxide production in the RVLM was measured using a lucigenin luminescence assay as described previously. 14, 15 Quantification of NAD(P)H oxidase activity was expressed relative to that in WKY rats treated with VEH; this level was assigned a value of 1.
Statistical analysis
All values are expressed as the means ± s.e.m. Comparisons between any two mean values were performed using Bonferroni's correction for multiple comparisons. Analysis of variance was used to compare all the parameters in all groups. Differences were considered to be statistically significant at a P value of o0.05.
RESULTS
Blood pressure, heart rate and urinary norepinephrine excretion Systolic blood pressure of SHRSPs was significantly lower in each TLM, CAN and HYD rats when compared with VEH rats after 4 weeks of treatment ( Figure 1a ) and there was no difference among TLM, CAN and HYD rats (Figure 1a) . However, heart rate in SHRSPs was significantly lower in TLM rats compared with CAN and HYD rats (Figure 1b) . In WKY rats, systolic blood pressure and heart rate were the same among the groups (Figures 1c and d) . Urinary norepinephrine excretion was significantly lower in TLM rats versus CAN, HYD and VEH rats in SHRSPs. However, urinary norepinephrine excretion was the same in CAN and VEH rats (Figure 2a) . In WKY rats, urinary norepinephrine excretion was the same among all groups (Figure 2b ).
TBARS levels and NAD (P) H oxidase activity in the RVLM
In SHRSPs, TBARS levels ( Figure 3a ) and NAD(P)H oxidase activity (Figure 3b ) in the RVLM rats were significantly lower in TLM rats versus CAN, HYD and VEH rats, but there was no difference between CAN and VEH rats. In WKY rats, TBARS levels ( Figure 3c ) and NAD(P)H oxidase activity (Figure 3d ) in the RVLM were the same between all groups.
Effects of microinjection of angiotensin II into the RVLM In SHRSPs, the pressor effects caused by the microinjection of angiotensin II into the RVLM were significantly smaller in TLM rats than in CAN, HYD or VEH rats (Figure 4a ), and they were the same in CAN and VEH rats (Figure 4a) . In WKY rats, the pressor effects caused by the microinjection of angiotensin II into the RVLM were the same among groups (Figure 4b ).
Effects of microinjection of tempol or apocynin into the RVLM In SHRSPs, the depressor effects caused by the microinjection of tempol (Figure 5a ) or apocynin (Figure 5b ) into the RVLM were significantly smaller in TLM rats than in CAN, HYD or VEH rats, and there was no difference between CAN and VEH rats. In WKY rats, the depressor effects caused by the microinjection of tempol (Figure 5c ) or apocynin (Figure 5d ) into the RVLM were the same in all groups.
DISCUSSION
In the present study, we demonstrated two major findings. First, orally administered TLM inhibits SNS activation through the reduction of oxidative stress via inhibition of AT 1 R in the RVLM of SHRSPs. Second, the sympathoinhibition caused by orally administered TLM in SHRSPs is independent of its depressor effect and is not a class effect of ARBs. These results suggest that orally administered TLM might have the potential to be a novel treatment for hypertension via sympathoinhibition.
SNS activation is determined mainly by neural activity in the RVLM in hypertensive patients. 5, 6 We demonstrated that oxidative stress in the brain causes hypertension through sympathoexcitation. 11, [15] [16] [17] 34, 35 We also demonstrated that AT 1 R-inducced oxidative stress in the RVLM causes SNS activation in hypertensive rats. 11, 14, 15 Direct inhibition of the AT 1 R in the RVLM inhibits SNS activation in hypertensive rats. 15, [18] [19] [20] Peripherally administered ARBs also inhibit the central actions of angiotensin II in the brain. [21] [22] [23] [24] [25] [26] [27] [28] Furthermore, we demonstrated that orally administered TLM inhibits SNS activation by reducing oxidative stress in the brains of hypertensive rats. 16 However, it has not been determined whether the sympathoinhibition caused by orally administered ARBs is a class effect of ARBs. 32 The effects of ARBs might differ depending on the pharmacokinetics and properties of each drug. 26 In the present study, orally administered TLM inhibits SNS activation and the angiotensin II-AT 1 R-NAD(P)H oxidase-oxidative stress pathway in the RVLM of SHRSPs. However, orally administered CAN or HYD does not have Sympathoinhibition by telmisartan in hypertensive rats T Kishi et al these results in SHRSPs despite having similar depressor effects. These results indicate that orally administered TLM might inhibit the AT 1 R in the RVLM. These effects are independent of its depressor effects and are not class effects of ARBs. The mechanisms by which sympathoinhibition, through the reduction of oxidative stress via inhibition of AT 1 R in the RVLM, is different between orally administered TLM and CAN should be discussed. In the present study, oxidative stress and NAD(P)H oxidase activity in the RVLM are reduced in the TLM-treated SHRSPs but not in the CAN-treated SHRSPs. The pressor effect caused by the microinjection of angiotensin II into the RVLM and the depressor effect caused by the microinjection of tempol or apocynin into the RVLM are significantly smaller in TLM-treated than in CAN-treated SHRSPs. These results suggest that the pathway of AT 1 R-NAD(P)H oxidase-oxidative stress in the RVLM is blocked by orally administered TLM but not by CAN. A previous study demonstrated that, following peripheral administration, TLM penetrates the blood-brain barrier in a dose-and time-dependent manner to inhibit centrally mediated effects of angiotensin II because of the high lipophilicity of TLM. 26 Previously, we also demonstrated that orally administered TLM inhibits SNS activation through the inhibition of AT 1 R in the brain of hypertensive rats. 16 We posit that orally administered TLM (2 mg kg À1 per day) can penetrate the blood-brain barrier and reach the RVLM of SHRSPs, whereas CAN (2 mg kg À1 per day) cannot. Furthermore, previous studies have demonstrated differences between TLM and CAN. [36] [37] [38] [39] Both TLM and CAN show clear efficacies. 36 However, the efficacy of CAN is linked to the presence of a carboxyl group at its imidazole-derived moiety, whereas TLM is efficacious despite the absence of a carboxyl group. 36 Moreover, in terms of inverse agonist activity, previous studies have demonstrated that CAN can stabilize AT 1 R in an inactive state, therefore acting as an 'inverse agonist,' in the absence of angiotensin II, whereas TLM does not have Sympathoinhibition by telmisartan in hypertensive rats T Kishi et al such an effect. [37] [38] [39] In terms of the agonist activity of peroxisome proliferator-activated receptor (PPAR)-g, a previous study suggested that orally administered rosiglitazone, a PPAR-g agonist, promotes a central antihypertensive effect via upregulation of PPAR-g and alleviation of oxidative stress in the RVLM of SHR. 40 Although both TLM and CAN function as partial agonists of PPAR-g, only TLM achieves this effect at therapeutic doses. 41 Further studies are necessary to investigate the differences in central effects elicited by the various ARBs in terms of efficacy, inverse agonist activity and PPAR-g agonist activity.
Several studies have suggested that orally administered CAN causes sympathoinhibition and attenuates the central effects of angiotensin II in the brain. 22, 24, 25, 28 Direct inhibition of AT 1 R in the RVLM or other areas of the brain inhibits SNS activation, 15, [18] [19] [20] and superfusion with CAN decreases the electrophysiological activity of RVLM neurons examined using the patch-clamp technique. 42 In previous studies demonstrating sympathoinhibition caused by orally administered CAN in hypertensive rats, the doses of CAN were greater (4, (ref. 22) 5, (ref. 24) or 10, (ref. 25) mg kg À1 per day) than those in the present study (2 mg kg À1 per day). However, Sakata et al. 28 demonstrated that 1 mg kg À1 per day of CAN for 2 weeks causes sympathoinhibition in SHR. Although blood pressure of SHRs in their study is lower than that of the SHRSPs in the present study, and the heart rate of the SHRs were similar to that of the WKY rats in their study, these previous studies suggested that the difference in sympathoinhibition between TLM and CAN in the present study may not be due to the dose of CAN. We hypothesize that orally administered CAN (2 mg kg À1 per day) was not sufficient to penetrate the blood-brain barrier of SHRSPs.
Interestingly, in the present study, sympathoinhibition through reduction of oxidative stress via inhibition of AT 1 R in the RVLM was not obtained in WKY rats. These results are compatible with our previous studies. 11, 15 In those studies, overexpression of superoxide dismutase in the RVLM or direct infusion of ARBs into the brain did not reduce oxidative stress and did not inhibit SNS activation in WKY rats. 11, 15 From these results, two explanations are possible. First, orally administered TLM (2 mg kg À1 per day) could not penetrate the blood-brain barrier, which is not as damaged in WKY rats. In hypertensive rats, the blood-brain barrier is damaged; 43, 44 thus, orally administered TLM can easily penetrate the blood-brain barrier of SHRSPs. This possibility would also support our results that orally administered ARB-induced sympathoinhibition through the reduction of oxidative stress via inhibition of the AT 1 R in the RVLM is dependent on the penetration of the blood-brain barrier. Second, the role of AT 1 R-induced oxidative stress on the regulation of SNS activation may differ between SHRSPs and WKY rats.
The increase in the number of hypertensive patients is a health problem because hypertension is considered to be a risk factor for cardiovascular diseases. 33 ARBs are widely used in hypertensive patients because of their powerful blood pressure-lowering effects and organ-protective effects. 33 However, one of the important treatment targets for hypertension is inadequate SNS activation, and it has not been determined whether ARBs have beneficial effects on SNS activation in hypertension. In the present study, we demonstrated that orally administered TLM, but not CAN, inhibits SNS activation through the reduction of oxidative stress via inhibition of AT 1 R in the RVLM of SHRSPs. These results are compatible with a previous clinical study, which indicated that TLM (40 mg per day) causes sympathoinhibition to a greater extent than losartan (50 mg per day) in hypertensive patients with diabetic nephropathy. 29 We also previously demonstrated that orally administered atorvastatin, azelnidipine or amlodipine also causes sympathoinhibition through the reduction of oxidative stress in the RVLM of SHRSPs. [45] [46] [47] However, the results of the present study could not directly elucidate the clinical benefits of TLM in hypertensive patients because the dose of TLM in the present study is not a clinical dose, and there are no clinical trials demonstrating the same reduction in heart rate obtained in the present study. Furthermore, damage to the blood-brain barrier may be much more significant in SHRSPs than in hypertensive human patients. To determine whether the benefits of There are several limitations to the present study. First, we examined the AT 1 R-NAD(P)H oxidase-oxidative stress pathway only in the RVLM. In addition to the RVLM, some important foci are involved in cardiovascular regulation, such as the nucleus tractus solitarii and the hypothalamus. 6 AT 1 R is rich in the specific brain nuclei that regulate SNS activation, such as the anteroventral third ventricle, paraventricular nucleus of the hypothalamus, nucleus tractus solitarii and RVLM. [48] [49] [50] Moreover, a high density of AT 1 R is present in the brain regions involved in the regulation of SNS activation, such as the circumventricular organs outside of the bloodbrain barrier, where peripherally administered ARBs are able to effect change without consideration of the blood-brain barrier, as well as inside of the blood-brain barrier. 50 The reduction of oxidative stress via inhibition of AT 1 R caused by orally administered TLM may not be a phenomenon unique to the RVLM. However, in the regulation of the SNS activation, the RVLM is the most important site. 5, 6 Furthermore, in the RVLM, oxidative stress is considered to be the most important sympathoexciting factor. 11, [15] [16] [17] For these reasons, the RVLM is the focus of the present study. Second, we did not examine the dose-dependency of sympathoinhibition caused by orally administered TLM or CAN and the long-term effect of orally administered TLM or CAN in the present study. Our previous study and the present study suggest that the degrees of sympathoinhibition and the depressor effects caused by orally administered TLM are significantly smaller in the present study (2 mg kg À1 per day) than in our previous study (5 or 10 mg kg À1 per day). 16 Third, we could not directly demonstrate that TLM penetrates the blood-brain barrier to reach the RVLM; in future studies we will measure the concentration of TLM in the brain tissue.
In conclusion, in the present study, orally administered TLM inhibits SNS activation through the reduction of oxidative stress via inhibition of AT 1 R in the RVLM of SHRSPs, and the effects are independent of its depressor effect and are not class effects of ARBs. These results suggest that orally administered TLM might have the potential to be a novel treatment for hypertension resulting from sympathoinhibition through the reduction of oxidative stress via inhibition of AT 1 R in the RVLM.
